Business - Briefly   

Aurobindo Pharma bags USFDA approval

HYDERABAD: The city-based bulk drugs major, Aurobindo Pharma, on Tuesday announced that it had bagged the U.S. Food and Drug Administration's approval for its product Citalopram oral solution 10mg/5mg. It already has FDA approval for Citalopram tablets of 10, 20 and 40 mg. A press release said Citalopram was a generic equivalent of Forest Laboratories' Celexa and belonged to a class of medication called selective serotonin re-uptake inhibitors (SSRIs).

Printer friendly page  
Send this article to Friends by E-Mail

Stories in this Section

Draft scheme to merge UWB with IDBI outlined
High industrial growth not to impact interest rates, says FM
Videocon close to acquiring Daewoo Electronics
Sensex recovers on strong industrial growth
UTI Mutual Fund expands product suite
Cashew council to celebrate golden jubilee from Sept. 15
Godrej to invest Rs. 20 crore in Chennai
Unison plans five-star hotel
NIIT unveils management programme for executives
Parametric expands ties with Newgen
Rupee ends higher
Exchange rates
Bullion rates
Yes Bank, Intel launch wi-fi banking network
Anti-asthma inhalation capsule launched
Govt. not to sell stake in PFC
Sun Micro launches Coimbatore operations
Optional scheme of Central Excise Department
Central Bank branch shifted to new premises
Punj Lloyd joins hands with Swissport
IDG establishes $150 m technology fund
Workshop on software development
Sonata partners Microsoft for ERP solutions
Patel Engineering acquires Michigan Engineers
Jawad Business Group's pact with AB Hotels
Eureka Forbes conducts health camp in south
Convergys wins HR excellence award
Aurobindo Pharma bags USFDA approval
Indo-Dutch joint venture formed
Sierra Atlantic partners Scalia
Cades embarks on expansion plan
Intel Capital invests $2 m in Ilantus Technologies
Kirloskar Toyoda signs agreement with Toyota Ind.
Syndicate Bank adds million new accounts in 2 months
MphasiS appoints new COO

Copyright © 2006, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu